These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 8486938)

  • 1. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies.
    Rosenqvist E; Høiby EA; Wedege E; Kusecek B; Achtman M
    J Infect Dis; 1993 May; 167(5):1065-73. PubMed ID: 8486938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine.
    Milagres LG; Gorla MC; Rebelo MC; Barroso DE
    FEMS Immunol Med Microbiol; 2000 Aug; 28(4):319-27. PubMed ID: 10891656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of IgG and IgM to meningococcal outer membrane proteins in relation to carriage of Neisseria meningitidis or Neisseria lactamica.
    Kremastinou J; Tzanakaki G; Pagalis A; Theodondou M; Weir DM; Blackwell CC
    FEMS Immunol Med Microbiol; 1999 May; 24(1):73-8. PubMed ID: 10340715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination.
    Sjursen H; Wedege E; Rosenqvist E; Naess A; Halstensen A; Matre R; Solberg CO
    APMIS; 1990 Dec; 98(12):1061-9. PubMed ID: 2126441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis.
    Rosenqvist E; Musacchio A; Aase A; Høiby EA; Namork E; Kolberg J; Wedege E; Delvig A; Dalseg R; Michaelsen TE; Tommassen J
    Infect Immun; 1999 Mar; 67(3):1267-76. PubMed ID: 10024570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease.
    Fischer M; Carlone GM; Holst J; Williams D; Stephens DS; Perkins BA
    Vaccine; 1999 May; 17(19):2377-83. PubMed ID: 10392619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine.
    Naess LM; Aarvak T; Aase A; Oftung F; Høiby EA; Sandin R; Michaelsen TE
    Vaccine; 1999 Feb; 17(7-8):754-64. PubMed ID: 10067680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine.
    Aase A; Høiby EA; Michaelsen TE
    Scand J Immunol; 1998 Apr; 47(4):388-96. PubMed ID: 9600322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status of a group B Neisseria meningitidis vaccine.
    Frasch CE
    Eur J Clin Microbiol; 1985 Dec; 4(6):533-6. PubMed ID: 3937731
    [No Abstract]   [Full Text] [Related]  

  • 10. A linear B-cell epitope on the class 3 outer-membrane protein of Neisseria meningitidis recognized after vaccination with the Norwegian group B outer-membrane vesicle vaccine.
    Delvig AA; Wedege E; Caugant DA; Dalseg R; Kolberg J; Achtman M; Rosenqvist E
    Microbiology (Reading); 1995 Jul; 141 ( Pt 7)():1593-600. PubMed ID: 7551027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection.
    Rosenqvist E; Harthug S; Frøholm LO; Høiby EA; Bøvre K; Zollinger WD
    J Clin Microbiol; 1988 Aug; 26(8):1543-8. PubMed ID: 3139705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-induced IgG antibodies to the linear epitope on the PorB outer membrane protein promote opsonophagocytosis of Neisseria meningitidis by human neutrophils.
    Delvig AA; Michaelsen TE; Aase A; Hoiby EA; Rosenqvist E
    Clin Immunol Immunopathol; 1997 Jul; 84(1):27-35. PubMed ID: 9191881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.
    Wedege E; Kuipers B; Bolstad K; van Dijken H; Frøholm LO; Vermont C; Caugant DA; van den Dobbelsteen G
    Infect Immun; 2003 Jul; 71(7):3775-81. PubMed ID: 12819059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine.
    Claassen I; Meylis J; van der Ley P; Peeters C; Brons H; Robert J; Borsboom D; van der Ark A; van Straaten I; Roholl P; Kuipers B; Poolman J
    Vaccine; 1996 Jul; 14(10):1001-8. PubMed ID: 8873395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies.
    Rosenqvist E; Høiby EA; Bjune G; Bryn K; Closs O; Feiring B; Klem A; Nøkleby H; Frølm LO
    NIPH Ann; 1991 Dec; 14(2):169-79; discussion 180-1. PubMed ID: 1687481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody studies in mice of outer membrane antigens for use in an improved meningococcal B and C vaccine.
    Milagres LG; Cristina M; Brandileone MC; Sacchi CT; Vieira VS; Zanella RC; Frasch CE
    FEMS Immunol Med Microbiol; 1996 Jan; 13(1):9-17. PubMed ID: 8821393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease.
    Norheim G; Arne Høiby E; Caugant DA; Namork E; Tangen T; Fritzsønn E; Rosenqvist E
    Vaccine; 2004 Jun; 22(17-18):2171-80. PubMed ID: 15149774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.
    Wedege E; Høiby EA; Rosenqvist E; Bjune G
    Infect Immun; 1998 Jul; 66(7):3223-31. PubMed ID: 9632589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage.
    Delbos V; Lemée L; Bénichou J; Berthelot G; Deghmane AE; Leroy JP; Houivet E; Hong E; Taha MK; Caron F;
    Vaccine; 2013 Sep; 31(40):4416-20. PubMed ID: 23856330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with recombinant truncated Neisseria meningitidis-Macrophage Infectivity Potentiator (rT-Nm-MIP) protein induces murine antibodies that are cross-reactive and bactericidal for Neisseria gonorrhoeae.
    Humbert MV; Christodoulides M
    Vaccine; 2018 Jun; 36(27):3926-3936. PubMed ID: 29803329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.